Insider Trading April 16, 2026 07:19 PM

Aehr Test Systems Director Sells $399K in Stock as Company Posts Record AI Burn-In Order and Mixed Q3 Results

Director Laura Oliphant disposes 4,665 shares; Aehr reports a $41 million hyperscale order and posts mixed quarterly results with elevated bookings.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
AEHR

Laura Oliphant, a director at Aehr Test Systems, sold 4,665 shares on April 16, 2026, for $399,267. The transaction occurred while the stock has risen sharply over the past year but currently trades below the sale price. Aehr also announced a record $41 million production order from a hyperscale customer for package-level burn-in of custom AI processor ASICs, and reported Q3 2026 results that beat EPS estimates but missed revenue expectations. Analysts updated price targets and reiterated coverage in response to strong bookings and a growing backlog.

Aehr Test Systems Director Sells $399K in Stock as Company Posts Record AI Burn-In Order and Mixed Q3 Results
AEHR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Laura Oliphant sold 4,665 shares on April 16, 2026, for $85.5879 per share, totaling $399,267; the sale was executed through a trust.
  • Aehr announced a record $41 million production order from a hyperscale customer for package-level burn-in of custom AI processor ASICs, including Sonoma high-power systems, burn-in modules and device-specific sockets, with deliveries starting in fiscal 2027.
  • Q3 2026 results showed EPS of -$0.05 (better than -$0.07 forecast) and revenue of $10.3 million (missing the $10.8 million estimate); quarterly bookings were $37.2 million with an effective backlog exceeding $50 million.

Laura Oliphant, a director on the board of Aehr Test Systems (NASDAQ: AEHR), sold 4,665 shares of the company's common stock on April 16, 2026, at $85.5879 per share, for a total consideration of $399,267. The disposition was executed through a trust and follows a period of pronounced share-price appreciation for the company.

Following the sale, Oliphant holds 18,432 shares in total, a figure that the company reports includes unvested restricted stock units. At the time of the transaction the stock had recorded an 891% gain over the past year, though the share price later traded at $80.85, which is below Oliphant's transaction price.

Market-value and earnings context cited in market analysis note that Aehr carries a market capitalization of $2.55 billion while reporting negative earnings of $0.38 per share on a trailing basis. InvestingPro analysis referenced in company coverage flags the stock as appearing overvalued relative to its Fair Value.


In a separate operational update, Aehr Test Systems disclosed it received a record $41 million production order from a hyperscale customer. The order, described as the largest in the company’s history, is for package-level burn-in of custom AI processor ASICs and includes Sonoma high-power package-level test and burn-in systems, burn-in modules, and device-specific sockets. Deliveries tied to this production order are scheduled to begin in the company’s fiscal 2027.

Financial results for Q3 2026 were mixed. Aehr reported earnings per share of -$0.05, which was better than the consensus forecast of -$0.07, yet revenue for the quarter was $10.3 million, missing the $10.8 million estimate.

Analysts responded to the combination of bookings and results with price-target adjustments while maintaining their respective ratings. Freedom Broker raised its price target to $61 from $38 and kept a Hold rating. Lake Street increased its target to $56 from $50 and maintained a Buy rating. Both firms cited strong bookings momentum as a rationale for their actions; Aehr reported $37.2 million in quarterly bookings and an effective backlog that exceeds $50 million.

These developments - a sizable hyperscale production order, elevated bookings and backlog, and a quarter that beat on EPS but missed revenue - were highlighted by analysts in their revisions and commentary. The company’s disclosed metrics reflect ongoing engagement with a hyperscale AI customer and a concentration of demand in package-level burn-in systems for custom AI ASICs.

Risks

  • Valuation concern: Market analysis indicates Aehr appears overvalued relative to its Fair Value with a market capitalization of $2.55 billion while reporting negative earnings of $0.38 per share - impacts equity investors and valuation-sensitive strategies.
  • Revenue delivery risk: Despite an EPS beat, Aehr missed revenue expectations in Q3 2026, which may affect near-term top-line outlook and investor sentiment in the semiconductor test and AI hardware sectors.
  • Concentration and timing risk: The record $41 million production order is tied to a hyperscale customer with deliveries beginning in fiscal 2027, creating execution and timing dependencies that could influence bookings realization and supply-chain planning in semiconductor capital equipment markets.

More from Insider Trading

Executive Capital Commitment at Bed Bath & Beyond Aug 6, 2026 EXLService President Vikas Bhalla Executes $384,890 Share Sale Under Pre-Existing Trading Plan Aug 6, 2026 Arcutis Biotherapeutics Executive Divests Shares Amid Strong Financial Backdrop Aug 6, 2026 Executive Capital Deployment and Leadership Restructuring at Hanover Bancorp Aug 3, 2026 Adaptive Biotechnologies Executive Liquidates Shares as Volume Metrics Diverge From Profitability Aug 3, 2026